

# Systematic review and meta-analysis of gallstone disease treatment outcomes in early cholecystectomy versus conservative management/delayed cholecystectomy

Bhavani Shankara Bagepally ,<sup>1</sup> Madhumitha Haridoss,<sup>1</sup> Akhil Sasidharan,<sup>1</sup> Kayala Venkata Jagadeesh,<sup>2</sup> Nikhil Kumar Oswal<sup>3</sup>

**To cite:** Bagepally BS, Haridoss M, Sasidharan A, *et al.* Systematic review and meta-analysis of gallstone disease treatment outcomes in early cholecystectomy versus conservative management/delayed cholecystectomy. *BMJ Open Gastro* 2021;**8**:e000675. doi:10.1136/bmjgast-2021-000675

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/bmjgast-2021-000675>).

Received 5 April 2021  
Accepted 4 July 2021



© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

<sup>1</sup>ICMR-NIE Health Technology Assessment Resource Centre, ICMR-National Institute of Epidemiology, Chennai, Tamil Nadu, India

<sup>2</sup>Health Technology Assessment in India (HTAI) Secretariat, Department of Health Research, MoHFW, GOI, New Delhi, India

<sup>3</sup>Department of Surgery, Oswal Hospital, Bangarpet, Karnataka, India

## Correspondence to

Dr Bhavani Shankara Bagepally; bagepally.bs@gov.in

## ABSTRACT

**Background** The effectiveness of early cholecystectomy for gallstone diseases treatment is uncertain compared with conservative management/delayed cholecystectomy.

**Aims** To synthesise treatment outcomes of early cholecystectomy versus conservative management/delayed cholecystectomy in terms of its safety and effectiveness.

**Design** We systematically searched randomised control trials investigating the effectiveness of early cholecystectomy compared with conservative management/delayed cholecystectomy. We pooled the risk ratios with a 95% CI, also estimated adjusted number needed to treat to harm.

**Results** Of the 40 included studies for systematic review, 39 studies with 4483 patients are included in meta-analysis. Among the risk ratios of gallstone complications, pain (0.38, 0.20 to 0.74), cholangitis (0.52, 0.28 to 0.97) and total biliary complications (0.33, 0.20 to 0.55) are significantly lower with early cholecystectomy. Adjusted number needed to treat to harm of early cholecystectomy compared with conservative management/delayed cholecystectomy are, for pain 12.5 (8.3 to 33.3), biliary pancreatitis >1000 (50–100), common bile duct stones 100 (33.3 to 100), cholangitis (100 (25–100), total biliary complications 5.9 (4.3 to 9.1) and mortality >1000 (100 to 100 000).

**Conclusions** Early cholecystectomy may result in fewer biliary complications and a reduction in reported abdominal pain than conservative management.

**PROSPERO registration number** 2020 CRD42020192612.

## INTRODUCTION

Cholelithiasis/gallstone disease management imposes a significant burden on healthcare systems worldwide, costing about 6.5 billion dollars/year only in the USA itself.<sup>1</sup> The prevalence of gallstones ranges from 0.1% to 50.5% worldwide.<sup>2</sup> Although gallstone disease is usually asymptomatic, certain risk

## Summary box

### What is already known about this subject?

► Although from individual trials, early cholecystectomy is considered safe and effective compared with conservative management/delayed cholecystectomy, but the synthesised evidence is limited.

### What are the new findings?

- Gallstone-related complications are significantly lower with early cholecystectomy compared with observation management, endoscopic management and delayed cholecystectomy.
- The perioperative and intraoperative complications are significantly higher with early cholecystectomy compared with delayed cholecystectomy.
- Overall early cholecystectomy is effective compared with conservative management/delayed cholecystectomy for gallstones.

### How might it impact clinical practice in the foreseeable future?

► Our meta-analysis has reported both adjusted and unadjusted number needed to treat to harm, which is a beneficial measure for the surgeons and policy-makers to arrive at appropriate clinical and policy decision-making, respectively.

factors drive the progression from asymptomatic to symptomatic illness, with or without complications, making it imperative to treat.<sup>3</sup> Gallstone-related complications include common bile duct stones (CBD stones)/choledocholithiasis, acute cholecystitis, cholangitis, gallstone pancreatitis and others.<sup>3</sup> Surgical removal of the gallbladder (known as cholecystectomy) is the treatment of choice for symptomatic gallstones.<sup>4</sup> Laparoscopic cholecystectomy is the preferred treatment option over open cholecystectomy for gallstones and cholecystitis.<sup>5</sup> However,



approximately 12% of patients who have undergone cholecystectomy continue to experience pain and recurrent gallstone-related symptoms.<sup>6</sup>

Conservative management (CM), involving pain and symptomatic treatment with gallbladder in situ, carries no risk of operative complications and is also considered an alternative to cholecystectomy.<sup>7</sup> However, among conservatively managed patients with uncomplicated gallstones, recurrence of gallstone symptoms and subsequent development of gallstone-related complications often lead to cholecystectomy.<sup>8</sup> Similarly, several randomised control trials (RCTs) comparing early versus delayed cholecystectomy (DC) for gallstone disease reported recurrence of symptoms/complications in the waiting period before surgery and also reported higher postsurgical complications with delayed surgery.<sup>9</sup> Thus, the effectiveness of early cholecystectomy (EC) over CM/DC is ambiguous. Therefore, we aimed to conduct this systematic review and meta-analysis to synthesise treatment outcomes between EC and CM/DC. The study's objective is to synthesise treatment outcomes such as (1) gallstone-related complications between EC and CM/DC (2) surgical complications, length of hospital stays and operative time between early and DC.

## METHODS

### Screening and study selection

We carried out this systematic review and meta-analysis in compliance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and registered the protocol at PROSPERO.<sup>10 11</sup> We systematically searched the studies indexed in PubMed-Medline, Scopus and Embase. The search terms were constructed based on domains of population, intervention, comparator and outcome (PICO) as described below. The search terms were combined using Boolean operator 'OR' within the same domains, and Boolean operator 'AND' between domains of PICO as described in online supplemental tables 1–3. An initial search was performed on 16 June 2020 and an updated search was performed on 12 January 2021.

According to the inclusion criteria, search results were screened for eligibility. The population included individuals with gallstones (cholelithiasis/cholecystolithiasis) or CBD stones (choledocholithiasis) or acute cholecystitis or gallstone pancreatitis. The intervention included surgical removal of the gallbladder through open or laparoscopic methods, where surgery was performed on an emergency basis or within 7 days, treated as EC. The comparator is CM and DC. CM included both observation management (OM) (also known as wait and watch strategy) and Endoscopic management (EM). Under OM, this study considered patients with gallstones who were symptomatically managed using pain killer, antibiotics, diet and lifestyle changes. Under EM, this study considered patients who underwent endoscopic removal of CBD stones with gallbladder left in situ. In DC, we

considered patients who were initially managed conservatively and later underwent cholecystectomy after 6 weeks. Outcomes included complications related to gallstone disease, perioperative, intraoperative and postoperative complications with cholecystectomy, length of hospital stays, operative time and the studies included were RCTs. Nonrandomised trials, observational studies, reviews and studies published in non-English languages for which a translation could not be obtained were excluded. Studies were also excluded for their selection of PICO, that is not of study's interest.

Titles and abstracts of studies listed from the electronic database search were meticulously screened independently by authors (BSB, MH, AS) using Rayyan-web application.<sup>12</sup> After screening, authors independently reviewed and selected studies based on inclusion and exclusion criteria with authors' mutual consensus (figure 1).

### Data extraction and management


All relevant details were extracted from the studies included, using a specific data extraction form. Data extracted include study characteristics (study design, location of study etc), participant characteristics (age, gender, duration of symptoms and timing of surgery), intervention, comparators and treatment outcomes (gallstone symptoms and complications, surgical complications). All the data for pooling were extracted as reported in the primary studies. For quality control, data extraction was performed by one reviewer and cross checked by another reviewer (BSB, MH). Any discrepancies between authors were resolved by discussion and consulting with a third reviewer (AS), whenever necessary. The extracted data were checked and used for further analysis after confirmation of its consistency.

### Assessment of risk of bias

We assessed the risk of bias using a revised Cochrane risk of bias tool (RoB-2 tool) for randomised trial.<sup>13</sup> RoB-2 tool comprises five domains: bias arising from randomisation process, deviation from intended intervention, missing outcome data, bias in the measurement of outcome and selection of reported results. The judgement regarding the risk of bias was determined by means of signalling questions with responses as 'yes', 'probably yes', 'probably no', 'no' and 'no information'. Two authors (MH and KVJ) independently assessed the risk of bias; later, a consensus was reached for any disagreement through discussion. However, a third reviewer's opinion (BSB) was obtained wherever necessary. The overall risk of bias was ascertained as high, some concerns or low for each study.

### Statistical analysis

Risk ratio along with its 95% CI was estimated for each complication from individual studies. Subsequently, risk ratios were pooled across studies using a random effects DerSimonian and Laird method considering possible



**Figure 1** Preferred Reporting Items for Systematic Reviews and Meta-Analyses flowchart of study selection.

heterogeneity across studies. For continuous variables, such as operation time and duration of hospital stay, mean difference and its 95% CI were estimated for individual studies and then pooled using a random-effects DerSimonian and Laird method. While performing the analysis, zero cells were corrected by adding 0.5.

### Assessment of heterogeneity

Heterogeneity was assessed using visual inspection of forest plots, Cochran-Q test and  $I^2$  statistics.  $I^2$  describes the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance).  $I^2$  values in our analysis were interpreted using the standards laid down in Cochrane’s handbook for Systematic Reviews of Interventions.<sup>14</sup> Cochran’s Q is the weighted sum of squared differences between individual study effects and the pooled effect across studies, with the weights being those used in the pooling method. Q is a  $\chi^2$  statistic with k (number of studies) minus one degree of freedom. If the  $Q(k-1)$  value is greater than the tabulated value (obtained using df) and p value is  $<0.1$ , then the heterogeneity is considered to be present.<sup>15</sup>

### Analysis of subgroups

Results were further explored using subgroup analysis based on intervention and comparators: EC versus OM (EC vs OM), EC versus EM and EC versus DC. A subgroup analysis of baseline gallstone complications (CBD stones/acute cholecystitis/gallstone pancreatitis) was performed within each comparison to address the heterogeneity of patients included in the systematic review. We also performed a subgroup analysis, to determine whether

the timing of surgery influenced the surgical complications. We have also performed a separate analysis of EC with CM alone (combining OM and EM). Risk ratios and mean differences were pooled between all interventions and comparators; however, perioperative and intraoperative complications were pooled only among early versus DC studies.

### Estimation of number of needed to harm

In this systematic review and meta-analysis, we additionally estimated the number needed to treat to harm (NNTH) for each outcome.<sup>16</sup> NNTH is defined as ‘the number of people exposed to a given treatment such that on average and over a given follow-up period one additional person experiences the adverse effect of interest because of the treatment’. It expresses the additional absolute risk of an adverse effect conferred by treatment and is, therefore, a useful and intuitively understandable decision-making tool for practicing clinicians.<sup>16</sup> As there is no consensus for the calculation of NNTs from pooled meta-analysis, we estimated the NNTH for each outcome using the two approaches suggested.<sup>17</sup> In the first approach, the log of risk difference (RD) and its 95% CIs between intervention and comparator for each complication was estimated. RDs were then pooled across studies using a random-effect model. Following, mean NNTH for each complication and its 95% CI were calculated as the inverse of mean and inverse of upper and lower limits of 95% CI of pooled RD, respectively.<sup>18</sup>

$$NNTH = \frac{1}{\text{pooled RD}}$$



We also calculated adjusted NNTH using the method suggested by Furukawa *et al*<sup>19</sup> and recent evidence synthesis.<sup>17</sup> We calculated adjusted NNTH using the following formula.

$$NNTH_{adjusted} = \frac{1}{(1-RR)*PEER}$$

where RR is pooled relative risk, PEER is the patient expected event rate. The PEER was calculated as the ratio of the total frequency of complication among comparators to that of the total number of comparators in respective pooled studies.

### Assessment of publication bias

Publication bias was assessed using a funnel plot (asymmetry) and Egger's test ( $p < 0.05$ ) of the effective measures, only if sufficient (at least 10) number of studies were available for pooling.<sup>20 21</sup> Furthermore, on identifying asymmetry in the funnel plot, the source of asymmetry was explored using a contour-enhanced funnel plot. Data were recorded using a Microsoft Excel sheet and analysed using Stata software V.16.<sup>22</sup> Two-sided  $p < 0.05$  was considered statistically significant except for the subgroup analysis and heterogeneity test, wherein  $p < 0.10$  was regarded as significant.

## RESULTS

We retrieved a total of 6494 studies through our initial and updated search, out of which 40 studies were included for systematic review, as shown in the PRISMA flow diagram (figure 1). We had excluded one study from the meta-analysis since no information on complications was reported.<sup>23</sup> Therefore, 39 studies with 4483 patients with gallstone disease (intervention—EC,  $n=2265$  and comparator (CM/DC),  $n=2218$ ) were included in meta-analysis.<sup>8 24-61</sup> Characteristics of included studies are provided in online supplemental table 4.

Patient's mean age was 53.47 years and 54.41 years in intervention and comparators, respectively. Sample sizes in individual studies ranged from 15 to 314 patients. In total, 6, 3 and 31 studies that compared EC versus OM,<sup>8 54-58</sup> EC versus EM<sup>59-61</sup> and EC versus DC,<sup>23-53</sup> respectively, were analysed. Among the 32 studies, which reported gender proportions, 26 studies (81.25%) had a higher proportion of female participants. Only 9 out of 40 included studies for systematic review were multicentric RCTs, and the rest were conducted in single centres. The baseline gallstone complications reported were acute cholecystitis, CBD stones, gallstone pancreatitis and uncomplicated gallstones in 20, 12, 7 and 1 study, respectively. Out of the 40 studies included in systematic review, open cholecystectomy was reported among 9 studies and cholecystectomy was performed laparoscopically among the rest. Duration of symptoms was reported only in seven studies, in which duration varied from 35.1 to 96 hours. In all the included EC versus DC studies, EC was performed within 7 days of randomisation and DC was performed after 6 weeks of randomisation.

### Risk of bias assessment

Out of 40 studies included in systematic review, 31 (77.5%) studies adequately followed the randomisation process. None of the included studies reported that patients and caregivers were blinded for the intervention under study, which might be due to the involvement of surgical intervention. Nine (22.5%) studies had shown deviations from the intended intervention. There were seven (17.5%) studies under the missing outcome data domain, one study (2.5%) in each domain for measurement of outcome data and selection of the reported results were assessed as high risk of bias. The overall risk of bias was estimated as low in 22 (55.0%), some concerns in 6 (15.0%) and high in 12 (30.0%) studies (online supplemental figure 1).

### Gallstone-related complications

#### Pain/biliary colic

We pooled the risk ratios of pain/biliary colic from 12 studies comparing EC and CM/DC, consisting of subgroups EC versus OM ( $n=5$ ),<sup>8 54 56-58</sup> EC versus EM ( $n=2$ )<sup>59 61</sup> and EC versus DC ( $n=5$ ).<sup>27 30 32 41 45</sup> The pooled risk ratio was 0.38 (0.20 to 0.74,  $I^2=51.57\%$ ) with moderate heterogeneity indicating significantly lower pain events with EC (see table 1). However, among subgroups, only in EC versus OM, there was significantly lower pain events with EC (0.39, 0.16 to 0.94,  $I^2=39.4\%$ ). The adjusted and unadjusted NNTH were 14.0 (10.9 to 33.4) and 12.5 (8.3 to 33.3), respectively. Subgroup analysis was conducted based on baseline gallstone complications within each comparison (EC vs OM, EC vs EM and EC vs DC). In EC versus OM, subgroups included were patient with (1) CBD stones, (2) uncomplicated gallstones and (3). acute cholecystitis. The pooled risk ratio shows significantly lower pain events with EC compared with OM in CBD stones and uncomplicated gallstones, whereas in acute cholecystitis, no significant difference was observed (online supplemental figure 3). In EC versus EM, subgrouping based on baseline gallstone complications was not performed due to lack of published studies. In EC versus DC, one study each for acute cholecystitis<sup>30</sup> and CBD stones<sup>45</sup> and three studies for gallstone pancreatitis<sup>22 27 36</sup> were identified. Significantly lower pain was observed in the EC compared with DC for acute cholecystitis and CBD stones, whereas for gallstone pancreatitis, no significant difference was observed between EC and DC (online supplemental figure 3). The funnel plot for EC versus DC shows asymmetry ( $p=0.508$ ), indicating publication bias (online supplemental figure 4). Separate analysis of pain in EC versus CM alone (combining OM and EM) showed significantly lower pain events in EC (online supplemental table 5).

#### Biliary pancreatitis

We pooled the risk ratios of biliary pancreatitis from eight studies consisting of subgroups EC versus OM ( $n=3$ ),<sup>8 57 58</sup> EC versus EM ( $n=2$ )<sup>59 60</sup> and EC versus DC ( $n=3$ ).<sup>27 32 41</sup> The pooled risk ratio was estimated as 0.47 (0.221.03,

**Table 1** Pooled risk ratios and NINTH of gallstone-related complications with subgroups based on intervention

Complications	Subgroup (number of studies)	RR (95% CI)	I <sup>2</sup> (%)	Q	NINTH_adjusted (95% CI)	NINTH_unadjusted (95% CI)	References
Pain/biliary colic	Overall (n=12)	0.38 (0.2 to 0.74)	51.57	22.72	14.0 (10.9 to 33.4)	12.5 (8.3 to 33.3)	
	EC vs OM (n=5)	0.39 (0.16 to 0.94)	39.70	6.63	10.4 (7.6 to 105.97)	12.5 (5.9 to 100.0)	8 54 56–58
	EC vs EM (n=2)	0.35 (0.06 to 2.28)	0	0.27	34.2 (17.4 to 23.7)	33.33 (12.5 to 100.0)	59 61
	EC vs DC (n=5)	0.33 (0.08 to 1.33)	74.68	15.80	14.8 (10.8 to 30.0)	14.0 (6.7 to very high)	27 30 32 41 45
CBD stones	Overall (n=4)	0.50 (0.14 to 1.78)	0	0.40	81.4 (47.3 to 52.2)	100.0 (33.3 to 100.0)	
	EC vs OM (n=2)	0.35 (0.06 to 2.15)	0	0	39.2 (27.1 to 22.2)	50.0 (25 to 100.0)	8 57
	EC vs EM (n=0)	–	–	–	–	–	–
	EC vs DC (n=2)	0.70 (0.12 to 4.29)	0	0.12	203.3 (19.0 to 69.3)	100.0 (33.3 to 50.0)	27 45
Biliary pancreatitis	Overall (n=8)	0.47 (0.22 to 1.03)	0	3.90	44.9 (30.5 to 794)	>1000 (50 to 100.0)	
	EC vs OM (n=3)	1.48 (0.24 to 9.29)	0	0.30	-383.3 (22.2 to 242.1)	100.0 (33.3 to 100.0)	8 57 58
	EC vs EM (n=2)	0.58 (0.07 to 4.67)	0	0.25	161.9 (18.5 to 73.1)	100.0 (33.3 to 50.0)	59 60
	EC vs DC (n=3)	0.34 (0.13 to 0.86)	0	1.34	16.3 (12.3 to 76.7)	17.0 (9.1 to 100.0)	27 32 41
Cholangitis	Overall (n=6)	0.52 (0.28 to 0.97)	0	3.76	29.6 (19.8 to 474.4)	100.0 (25.0 to 100.0)	
	EC vs OM (n=4)	0.79 (1.47 to 0.10)	0	2.96	5.8 (4.2 to 9.4)	Could not calculate	54–56 58
	EC vs EM (n=2)	1.00 (0.21 to 4.84)	0	3.76	Could not calculate	–	60 61
	EC vs DC (n=0)	–	–	–	–	–	–
Mortality/death	Overall (n=15)	0.74 (0.48 to 1.15)	0	6.81	118.3 (59.2 to 205.1)	>1000 (100 to 1 00000)	
	EC vs OM (n=4)	0.80 (0.48 to 1.35)	0	2.83	54.3 (20.9 to 31.0)	100.0 (25.0 to 100.0)	54 56–58
	EC vs EM (n=2)	0.75 (0.17 to 3.29)	0	0.03	147.0 (16.0 to 44.3)	>1000 (33.3 to 50.0)	60 61
	EC vs DC (n=10)	0.55 (0.20 to 1.50)	0	3.56	186.9 (105.1 to 168.2)	>1000 (100.0 to 100.0)	24 27 30 32–35 42 45 49
Total number of biliary complications	Overall (n=11)	0.33 (0.2 to 0.55)	68.24	31.48	5.7 (4.8 to 8.5)	5.9 (4.3 to 9.1)	
	EC vs OM (n=5)	0.33 (0.19 to 0.56)	38.13	6.47	5.2 (4.3 to 7.9)	5.3 (3.7 to 10)	8 55–58
	EC vs EM (n=1)	0.31 (0.09 to 1.07)	–	–	7.2 (5.5 to 71.4)	7.1 (3.7 to 100)	61
	EC vs DC (n=5)	0.29 (0.1 to 0.85)	83.75	24.62	6.6 (5.2 to 31.4)	6 (3.8 to 16.7)	27 30 32 41 45
Conversion to laparotomy	EC vs DC (n=19)	0.98 (0.71 to 1.36)	0	22.45	586.2 (32.6 to 40.4)	>1000 (50 to 50)	25–28 30 32 34 36 37 41 43 44 46–48 50–53

CBD, common bile duct; DC, delayed cholecystectomy; EC, early cholecystectomy; EM, endoscopic management; NINTH, number needed to treat to harm; OM, observation management; RR, risk ratio.

$I^2=0\%$ ) with low heterogeneity, indicating no significant difference between intervention and comparators (table 1). The adjusted and unadjusted NNTs were 44.9 (30.5 to 793.9) and >1000 (50.0 to 100.0) respectively. Among subgroups, in EC versus DC alone, significantly lower biliary pancreatitis events was observed in EC. Subgroup analysis based on baseline gallstone complications was not performed due to insufficient published literature. Separate analysis of biliary pancreatitis in EC versus CM alone (combining OM and EM) showed no significant difference in biliary pancreatitis between EC and CM (online supplemental table 5).

### CBD stones


We pooled the risk ratios of CBD stones from four studies consisting of EC versus OM (n=2)<sup>8 57</sup> and EC versus DC (n=2).<sup>27 45</sup> No studies with EC versus EM were available. The pooled risk ratio was 0.50 (0.14 to 1.78,  $I^2=0\%$ ) with low heterogeneity, indicating no significant difference between intervention and comparator. Results were found similar within each of the subgroups (see table 1). The adjusted and unadjusted NNTs were 81.4 (47.3 to 52.2) and 100.0 (33.3 to 100.0), respectively. Subgroup analysis based on baseline gallstone complications was not performed due to insufficient published studies. Separate analysis of CBD stones in EC versus CM alone (combining OM and EM) showed no significant difference in CBD stones between EC and CM (online supplemental table 5).

### Cholangitis

We pooled the risk ratios of cholangitis from six studies consisting of EC versus OM (n=4)<sup>54-56 58</sup> and EC versus EM (n=2).<sup>60 61</sup> No studies with EC versus DC were available, the pooled risk ratio was 0.52 (0.28 to 0.97,  $I^2=0\%$ ) with no heterogeneity, indicating significantly lower cholangitis events with intervention (see table 1). The adjusted and unadjusted NNTs were 21.6 (14.4 to 345.7) and 100.0 (25.0 to 100.0), respectively. Among subgroups, in EC versus OM, significantly lower cholangitis events were observed in the EC group (RR=0.46, 0.23-0.91,  $I^2=0\%$ ) (table 1). Subgroup analysis based on baseline gallstone complications was not performed due to insufficient published studies. Separate analysis of cholangitis in EC versus CM alone (combining OM and EM) showed significantly lower cholangitis events in EC (online supplemental table 5).

### Total biliary complications

We pooled the risk ratios of total biliary complications from 11 studies, including subgroups EC versus OM (n=5), EC versus EM (n=1) and EC versus DC (n=5) (see table 1). The pooled risk ratio was 0.33 (0.20 to 0.55,  $I^2=68.24\%$ ) with moderate heterogeneity indicating significantly lower total biliary complications with EC (figure 2). The adjusted and unadjusted NNTs were 6.3 (5.2 to 9.3) and 5.9 (4.3 to 9.1), respectively. Among the subgroups, in EC versus OM and EC versus DC, there



**Figure 2** Forest plot showing risk ratio of total biliary complications between early cholecystectomy and conservative management/delayed cholecystectomy with subgroups. CM, conservative management; DC, delayed cholecystectomy; EC, early cholecystectomy.

were significantly lower biliary complications with EC, but, not in EC versus EM subgroup. On subgroup analysis based on baseline gallstone complications, EC versus OM showed significantly lower total biliary complications in the EC for CBD stones and cholelithiasis (online supplemental figure 5). In EC versus DC, only one study each for acute cholecystitis<sup>30</sup> and CBD stones<sup>45</sup> was identified, showing significantly lower total biliary complications in EC than DC. For gallstone pancreatitis, three studies<sup>27 32 41</sup> were included, which showed no significant difference between EC and DC (online supplemental figure 6). The funnel plot showed asymmetry ( $p=0.476$ ), indicating publication bias (online supplemental figure 7). Separate analysis of total biliary complications in EC versus CM alone (combining OM and EM) showed significantly lower total biliary complications in EC (online supplemental table 5).

### Mortality

We pooled the risk ratios of mortality from 15 studies, including subgroups EC versus OM ( $n=4$ ),<sup>54 55 57 58</sup> EC versus EM ( $n=2$ )<sup>60 61</sup> and EC versus DC ( $n=9$ )<sup>24 27 30 32 34 35 42 45 49</sup> (see table 1). The pooled risk ratio was 0.74 (0.48 to 1.15,  $I^2=0\%$ ) with no heterogeneity, showing no significant difference between intervention and comparator. Similar results were found within each of the subgroups. The adjusted and unadjusted NNTH were 118.3 (59.16205.1) and  $>1000$  ( $100.0>1000$ ), respectively. Furthermore, subgroup analysis based on baseline gallstone complication showed no significant difference in mortality between EC and OM (online supplemental figure 8). Similarly, in EC versus DC, no significant difference in mortality was observed between the subgroups (online supplemental figure 9). The funnel plot showed asymmetry ( $p=0.553$ ), indicating publication bias (online supplemental figure 10). Separate analysis of mortality in EC versus CM alone (combining OM and EM) showed no significant difference in mortality between EC and CM (online supplemental table 5).

### Conversion to laparotomy

We pooled the risk ratios of conversion to laparotomy from 19 studies comparing EC and DC<sup>25–29 32 34 36 37 41 43 44 46–48 50–53</sup> (see table 1). The pooled risk ratio was 1.08 (0.18 to 1.43,  $I^2=2.01\%$ ) with low heterogeneity showing no significant difference between the intervention and comparator. The adjusted and unadjusted NNTH was  $>1000$  ( $100.0\geq 1000$ ). Subgroup analysis based on baseline gallstone complication showed no significant difference between subgroups (online supplemental figure 11). The funnel plot showed asymmetry ( $p=0.553$ ), indicating publication bias (online supplemental figure 12).

### Surgical complications

All surgical complications, including perioperative, intraoperative and postoperative complications, were compared between EC versus DC groups (see table 2). The perioperative and intraoperative complications

including a requirement of decompression, use of endoscopic pouches to retrieve specimen, enlargement of subumbilical incision events were significantly found higher in EC, indicating complexity. In contrast, adhesion events were lower in EC significantly. Other complications such as drain placement, bile leak, CBD injury, bleeding and total operative complications reported in the studies did not differ between EC and DC. On subgroup analysis, based on baseline gallstone complications, the events of perioperative and intraoperative complications did not differ between subgroups (data not shown). Subgroup analysis on the timing of surgery had shown similar results within the subgroups (online supplemental table 6).

The postoperative complications included as reported by the studies were wound infection, sepsis, postoperative bleeding, cystic duct leakage, chest infection, pneumonia, retained CBD stones, reoperation due to bile leak, pulmonary embolus, subphrenic abscess and readmission rate. Among the postoperative complications reported, only the readmission rate was significantly lower in the EC group. All other complications had shown no significant difference between EC versus DC groups. Subgroup analysis had also shown similar results between subgroups based on baseline gallstone complications (data not shown) and timing of surgery (online supplemental table 6).

The length of hospital stay was significantly lower in the EC group with a mean difference of  $-3.00$  ( $-3.99$  to  $-2.02$ ) days with high heterogeneity ( $I^2=92.61\%$ ) (figure 3). However, operative time (in minutes) did not differ between EC versus DC groups, with a mean difference of  $-4.84$  ( $-12.35$  to  $2.66$ ) with high heterogeneity ( $I^2=90.34\%$ ).


## DISCUSSION

In this systematic review and meta-analysis of RCTs, we compared clinical effectiveness of EC with CM/DC in terms of reducing recurrence of gallstone symptoms and occurrence of related complications. We also compared the surgical complications between EC and DC. Meta-analysis results showed that the gallstone-related complications, particularly pain/biliary colic, acute cholecystitis and cholangitis, were significantly lower among EC compared with CM/DC. The total biliary complications reported in the studies were significantly lower with EC in the EC versus OM subgroup, whereas no significant difference was observed in the EC versus EM and EC versus DC subgroups. The perioperative and intraoperative complications, including the requirement of decompression, use of endoscopic pouches to retrieve specimen, enlargement of subumbilical incision except for adhesion, were found to be significantly higher in EC, indicating the complexity of the procedure. Other perioperative and major postoperative complications, such as wound infection and bile leak, did not differ between EC versus DC groups.

**Table 2** Pooled risk ratios and NNT of surgical complications in early versus delayed cholecystectomy

Surgical complications (number of studies)	RR (95% CI)	I <sup>2</sup> (%)	Q	Adjusted NNT (95% CI)	Unadjusted NNT (95% CI)	References
<b>Perioperative and intraoperative complications</b>						
Adhesion (n=3)	0.58 (0.58 to 0.79)	0	1.81	5.2 (3.8 to 10.5)	5.0 (3.2 to 10)	25 33 37
Required decompression (n=5)	2.99 (2.99 to 5.13)	67.17	12.18	2.4 (1.2 to 6.4)	2.0 (1.6 to 3.2)	25 29 33 34 37
Drain placement (n=6)	1.63 (1.63 to 2.74)	73.79	19.07	4.9 (1.8 to 103.9)	5.0 (2.6 to 100)	25 29 33 34 37 44
Use of fifth port (n=4)	2.73 (2.73 to 16.98)	33.21	4.49	50.9 (5.5 to 157.1)	17.0 (6.7 to 33.3)	25 33 34 37
Use of endoscopic pouches to retrieve specimen (n=2)	1.56 (1.56 to 2.17)	0	0.78	5.4 (2.6 to 27.3)	6.0 (3.1 to 25)	25 37
Enlargement of subumbilical incision (n=2)	1.51 (1.51 to 2.19)	0	0.19	6.2 (2.6 to 78.6)	9.0 (2.8 to 7.7)	25 37
Bile leak (n=13)	1.18 (1.18 to 2.2)	0	6.67	314.6 (47.2 to 153.0)	100.0 (50 to >1000)	25 26 28–31 33 34 36 37 42 46 52
CBD injury (n=4)	0.82 (0.82 to 2.77)	0	0.77	265.6 (27.0 to 62.9)	100.0 (33.3 to 100.0)	28 33 52 53
Bleeding (n=6)	0.72 (0.72 to 1.91)	14.94	5.88	55.9 (17.2 to 21.4)	50.0 (16.7 to 50.0)	26 37 39 44 47 52
Total perioperative and intraoperative complications (n=5)	1 (1 to 2.51)	38.64	6.52	Could not be calculated	>1000 (33.3 to 33.3)	32 37 42 48 51
<b>Postoperative complications</b>						
Wound infection (n=16)	0.87 (0.87 to 1.31)	0	13.05	154.0 (47.7 to 64.6)	>1000 (50 to 50)	25 26 29–31 33–38 41 42 45 47 49
Sepsis (n=2)	0.31 (0.31 to 2.91)	0	0	90.6 (32.7 to 64.4)	100.0 (33.3 to 100.0)	42 49
Post-operative bleeding (n=4)	1.28 (1.28 to 5.3)	0	0.35	634.5 (41.3 to 257.5)	>1000 (100 to 100)	27 30 38 45
Cystic duct leakage (n=2)	1.99 (1.99 to 11.28)	0	0.33	92.4 (8.9 to 140.8)	>1000 (50 to 50)	27 45
Chest infection (n=4)	0.74 (0.74 to 2.55)	0	1.80	128.2 (21.5 to 42.7)	100.0 (25.0 to 50.0)	25 33 35 37
Basal pneumonia (n=4)	1.7 (1.7 to 6.27)	10.64	3.36	220.0 (29.2 to 285.2)	100.0 (33.3 to 100.0)	27 30 31 42
Retained CBD stones (n=5)	1.53 (1.53 to 4.27)	0	2.73	102.5 (16.6 to 120.7)	50.0 (33.3 to >1000)	31 33 37 42 47
Reoperation due to biliary leakage (n=4)	2.24 (2.24 to 7.87)	0	0.46	96 (17.3 to 330.6)	50 (25 to >1000)	36 38 42 47
Pulmonary embolus (n=3)	1.04 (1.04 to 5.89)	0	0.99	2337.5 (19.1 to 115.4)	100 (50 to 100)	27 39 49
Pulmonary pneumonia (n=2)	1.79 (1.79 to 6.91)	0	0.01	19.8 (2.7 to 29.6)	25 (7.1 to 16.7)	29 39
Subhepatic abscess (n=7)	0.83 (0.83 to 2.07)	0	3.54	320.3 (50.9 to 81.3)	>1000 (100 to 100)	30 31 35 36 41 45 49
Total postoperative complications (n=12)	0.94 (0.94 to 1.28)	0	8.02	113.3 (21.9 to 24.3)	100 (20 to 33.3)	25 29 32 34 36 38 41 45 46 48 51
Total surgical complications (n=17)	1.15 (1.15 to 1.45)	0	14.63	62.5 (20.8 to 104.2)	50 (20 to 50)	24 25 27 30–32 34 38 39 41–43 45 47 49 51 52
Readmission rate (n=3)	0.11 (0.11 to 0.48)	0	0.51	10.0 (9.2 to 17.1)	11 (6.7 to 33.3)	31 37 46
Conversion to laparotomy (n=20)	1 (1 to 1.34)	0	13.40	Could not be calculated	>1000 (50 to 50)	25–29 32–34 36 37 41 43 44 46–48 50–53
Need for ICU admission (n=2)	0.63 (0.63 to 5.1)	0	0.31	252.7 (22.8 to 101.6)	>1000 (50 to 100)	27 36

CBD, common bile duct; ICU, intensive care unit; NNT, number needed to treat to harm; RR, risk ratio.



**Figure 3** Forest plot showing mean difference in length of hospital stay between early and delayed cholecystectomy. DC, delayed cholecystectomy; EC, early cholecystectomy.

Previous systematic review and meta-analysis, comparing EC versus DC, had focused mainly on surgical complications, length of hospital stays and operative time with no/less emphasis on gallstone-related complications.<sup>9</sup> But, this review mainly focused on recurrent gallstone complications, thereby observing lower effectiveness of CM/DC from the pooled analysis. However, only fewer number of RCTs had reported these outcomes.<sup>27 30 32 41 45</sup> We also included few additional studies comparing EC versus DC, which were not included in any previous systematic review and meta-analysis.<sup>25 31 33 35 42 52</sup>

We also compared surgical outcomes in EC and DC groups to assess the impact of delayed surgery on surgical complications. Although studies involving CM reported surgical outcomes, not all the patients in the conservative arm underwent surgery. Therefore, we considered it appropriate to compare the surgical complications between EC and DC alone. Even though many previously published observational studies reported a higher risk for bile duct injury with EC in acute cholecystitis,<sup>62 63</sup> this meta-analysis suggests that there is no significant difference in terms of major postoperative complications such as bile duct injury, wound infection and bile leak between EC and DC. Our meta-analysis observed a higher risk for perioperative and intraoperative complications in EC similar to previous systematic review and meta-analysis.<sup>9</sup> Although there was no significant difference in major

surgical complications, this meta-analysis results revealed the recurrence or aggravation of gallstone symptoms during the waiting period of DC. Thus, EC seems to be a safer option based on existing pieces of evidence.

Our meta-analysis has also reported both adjusted and unadjusted NNTH, a beneficial measure to arrive at appropriate clinical decisions,<sup>64 65</sup> which is an added strength to our systematic review and meta-analysis. From this meta-analysis, it was clear that 12.5, >1000, 100, 100, 5.9 and >1000 patients need to undergo EC for one additional patient to have pain, biliary pancreatitis, CBD stones, cholangitis, total biliary complications and mortality, respectively, as compared with CM/DC. The review findings are in favour of EC, as a better treatment option, compared with CM/DC.

This systematic review and meta-analysis have some limitations. We compared EC with CM (including both OM and EM) and DC, which might have contributed some heterogeneity in data.

However, we have tried to address it through subgroup analysis. Few RCTs included in this study had a high risk of bias in the domains of randomisation and deviation from intended intervention. In most of the outcomes analysed, publication bias was also observed. We could not collect all the evidences, since full texts of some published studies that met with the inclusion criteria were not available even after requesting the corresponding authors.



The presence of many zero cells indicates rare events, which were statically handled through zero correction in our meta-analysis. We found that there are insufficient studies in many subgroups. Particularly, there was only one study that compared EC with OM for acute cholecystitis. Therefore, it is recommended to conduct further RCTs in future, which may bridge this knowledge gap.

In conclusion, EC is more effective in gallstone disease management, as it results in fewer biliary complications and a reduction in reported abdominal pain than DC/CM.

**Contributors** BSB: conceptualisation, data curation, formal analysis, inputs on original draft Investigation, methodology, software, review and editing. MH: conceptualisation, data curation, formal analysis, original draft. AS: data curation, review and editing. KVJ: data curation, review and editing. NKO: critical review and editing.

**Funding** The HTA resource centre ICMR-NIE is funded by the Department of Health Research Government of India.

**Disclaimer** Funders had no role in the conceptualisation, study conduction and manuscript preparation.

**Competing interests** None declared.

**Patient consent for publication** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** No data are available. All the data is available in the online supplementary material.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

#### ORCID ID

Bhavani Shankara Bagepally <http://orcid.org/0000-0003-0856-767X>

#### REFERENCES

- Shaffer EA. Epidemiology and risk factors for gallstone disease: has the paradigm changed in the 21st century? *Curr Gastroenterol Rep* 2005;7:132–40.
- Kratzer W, Mason RA, Kächele V. Prevalence of gallstones in sonographic surveys worldwide. *J Clin Ultrasound* 1999;27:1–7.
- Portincasa P, Di Ciaula A, Wang HH, et al. Medicinal treatments of cholesterol gallstones: old, current and new perspectives. *Curr Med Chem* 2009;16:1531–42.
- Portincasa P, Ciaula AD, Bonfrate L, et al. Therapy of gallstone disease: what it was, what it is, what it will be. *World J Gastrointest Pharmacol Ther* 2012;3:7–20.
- Keus F, de Jong J, Gooszen HG, et al. Laparoscopic versus open cholecystectomy for patients with symptomatic cholelithiasis. *Cochrane Database Syst Rev* 2006;80.
- Larsen TK, Qvist N. The influence of gallbladder function on the symptomatology in gallstone patients, and the outcome after cholecystectomy or expectancy. *Dig Dis Sci* 2007;52:760–3.
- Loozen CS, Oor JE, van Ramshorst B, et al. Conservative treatment of acute cholecystitis: a systematic review and pooled analysis. *Surg Endosc* 2017;31:504–15.
- Schmidt M, Sondenaa K, Vetrhus M, et al. A randomized controlled study of uncomplicated gallstone disease with a 14-year follow-up showed that operation was the preferred treatment. *Dig Surg* 2011;28:270–6.
- Lyu Y, Cheng Y, Wang B, et al. Early versus delayed laparoscopic cholecystectomy for acute cholecystitis: an up-to-date meta-analysis of randomized controlled trials. *Surg Endosc* 2018;32:4728–41.
- Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *J Clin Epidemiol* 2009;62:e1–34.
- Bagepally B. *Prospero registered protocol: clinical effectiveness of cholecystectomy compared with conservation management of symptomatic uncomplicated gallstones- a systematic review and meta-analysis*. Mendeley Data: Mendeley, 2021: 1–12.
- Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan-a web and mobile APP for systematic reviews. *Syst Rev* 2016;5:210.
- Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* 2019;366:14898.
- Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002;21:1539–58.
- The Cochrane Collaboration. *Cochrane handbook for systematic reviews of interventions*. 9 edn, 2008: 27.
- Bjerre LM, LeLorier J. Expressing the magnitude of adverse effects in case-control studies: "the number of patients needed to be treated for one additional patient to be harmed". *BMJ* 2000;320:503–6.
- Mendes D, Alves C, Batel-Marques F. Number needed to treat (NNT) in clinical literature: an appraisal. *BMC Med* 2017;15:112.
- Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. *BMJ* 1995;310:452–4.
- Furukawa TA, Guyatt GH, Griffith LE. Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses. *Int J Epidemiol* 2002;31:72–6.
- Deeks J, Altman D. *Effect measures for meta-analysis of trials with binary outcomes*, 2008: 313–35.
- Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315:629–34.
- . Stata Statistical Software: Release 16 [program]. College Station, TX StataCorp LLC; 2019.
- Aboulian A, Chan T, Yaghoubian A, et al. Early cholecystectomy safely decreases hospital stay in patients with mild gallstone pancreatitis: a randomized prospective study. *Ann Surg* 2010;251:615–9.
- Abbas A, Umair M, Isnain HG. Early cholecystectomy vs delayed cholecystectomy for gall stone pancreatitis. *Pakistan J Medical Health Sci* 2013;7:87–9 [https://www.researchgate.net/publication/329864905\\_Early\\_versus\\_interval\\_laparoscopic\\_cholecystectomy\\_in\\_acute\\_cholecystitis](https://www.researchgate.net/publication/329864905_Early_versus_interval_laparoscopic_cholecystectomy_in_acute_cholecystitis)
- Agrawal R, Sood KC, Agarwal B. Evaluation of early versus delayed laparoscopic cholecystectomy in acute cholecystitis. *Surg Res Pract* 2015;2015:1–7.
- Ammar SA, Bar MA, Shafy ME. Laparoscopic cholecystectomy after endoscopic retrograde cholangiopancreatography: the optimal timing for operation. *WJOLS* 2014;7:69–73.
- da Costa DW, Bouwense SA, Schepers NJ, et al. Same-Admission versus interval cholecystectomy for mild gallstone pancreatitis (PONCHO): a multicentre randomised controlled trial. *Lancet* 2015;386:1261–8.
- El Nakeeb A, Ezzet H, Askar W, et al. Early versus late cholecystectomy after clearance of common bile duct stones by endoscopic retrograde cholangiopancreatography: a prospective randomized study. *Surg Laparosc Endosc Percutan Tech* 2016;26:202–7.
- Gul R, Dar RA, Sheikh RA, et al. Comparison of early and delayed laparoscopic cholecystectomy for acute cholecystitis: experience from a single center. *N Am J Med Sci* 2013;5:414–8.
- Gutt CN, Encke J, Köninger J, et al. Acute cholecystitis: early versus delayed cholecystectomy, a multicenter randomized trial (ACDC study, NCT00447304). *Ann Surg* 2013;258:385–93.
- Järvinen HJ, Hästbacka J. Early cholecystectomy for acute cholecystitis: a prospective randomized study. *Ann Surg* 1980;191:501–5.
- Jee SL, Jarmin R, Lim KF, et al. Outcomes of early versus delayed cholecystectomy in patients with mild to moderate acute biliary pancreatitis: a randomized prospective study. *Asian J Surg* 2018;41:47–54.
- Khalid S, Iqbal Z, Bhatti AA. Early versus delayed laparoscopic cholecystectomy for acute cholecystitis. *J Ayub Med Coll Abbottabad* 2017;29:570–3.

- 34 Kolla SB, Aggarwal S, Kumar A, *et al.* Early versus delayed laparoscopic cholecystectomy for acute cholecystitis: a prospective randomized trial. *Surg Endosc* 2004;18:1323–7.
- 35 Lahtinen J, Alhava EM, Aukee S. Acute cholecystitis treated by early and delayed surgery. A controlled clinical trial. *Scand J Gastroenterol* 1978;13:673–8.
- 36 Lai PB, Kwong KH, Leung KL, *et al.* Randomized trial of early versus delayed laparoscopic cholecystectomy for acute cholecystitis. *Br J Surg* 1998;85:764–7.
- 37 Lo CM, Liu CL, Fan ST, *et al.* Prospective randomized study of early versus delayed laparoscopic cholecystectomy for acute cholecystitis. *Ann Surg* 1998;227:461–7.
- 38 Macafee DAL, Humes DJ, Bouliotis G, *et al.* Prospective randomized trial using cost-utility analysis of early versus delayed laparoscopic cholecystectomy for acute gallbladder disease. *Br J Surg* 2009;96:1031–40.
- 39 McArthur P, Cuschieri A, Sells RA, *et al.* Controlled clinical trial comparing early with interval cholecystectomy for acute cholecystitis. *Br J Surg* 1975;62:850–2.
- 40 Muhammedoğlu B, Kale IT. Comparison of the safety and efficacy of single-stage endoscopic retrograde cholangiopancreatography plus laparoscopic cholecystectomy versus two-stage ERCP followed by laparoscopic cholecystectomy six-to-eight weeks later: a randomized controlled trial. *Int J Surg* 2020;76:37–44.
- 41 Noel R, Arnelo U, Lundell L, *et al.* Index versus delayed cholecystectomy in mild gallstone pancreatitis: results of a randomized controlled trial. *HPB* 2018;20:932–8.
- 42 Norrby S, Herlin P, Holmin T, *et al.* Early or delayed cholecystectomy in acute cholecystitis? a clinical trial. *Br J Surg* 2005;70:163–5.
- 43 Ozkardeş AB, Tokaç M, Dumlu EG, *et al.* Early versus delayed laparoscopic cholecystectomy for acute cholecystitis: a prospective, randomized study. *Int Surg* 2014;99:56–61.
- 44 Rajcok M, Bak V, Danihel L, *et al.* Early versus delayed laparoscopic cholecystectomy in treatment of acute cholecystitis. *Bratisl Lek Listy* 2016;117:328–31.
- 45 Reinders JSK, Goud A, Timmer R, *et al.* Early laparoscopic cholecystectomy improves outcomes after endoscopic sphincterotomy for choledochocystolithiasis. *Gastroenterology* 2010;138:2315–20.
- 46 Roulin D, Saadi A, Di Mare L, *et al.* Early versus delayed cholecystectomy for acute cholecystitis, are the 72 hours still the rule?: a randomized trial. *Ann Surg* 2016;264:717–22.
- 47 Saber A, Hokkam EN. Operative outcome and patient satisfaction in early and delayed laparoscopic cholecystectomy for acute cholecystitis. *Minim Invasive Surg* 2014;2014:1–4.
- 48 Salman B, Yilmaz U, Kerem M, *et al.* The timing of laparoscopic cholecystectomy after endoscopic retrograde cholangiopancreatography in cholelithiasis coexisting with choledocholithiasis. *J Hepatobiliary Pancreat Surg* 2009;16:832–6.
- 49 Stone HH, Fabian TC, Dunlop WE. Gallstone pancreatitis: biliary tract pathology in relation to time of operation. *Ann Surg* 1981;194:305–12.
- 50 Verma S, Agarwal PN, Bali RS. *Early versus delayed laparoscopic cholecystectomy for acute cholecystitis: a prospective randomized trial.*
- 51 Yadav RP, Adhikary S, Agrawal CS, *et al.* A comparative study of early vs. delayed laparoscopic cholecystectomy in acute cholecystitis. *Kathmandu Univ Med J* 2009;7:16–20.
- 52 Zahur S, Rabbani S, Andrabi SIH. Early vs interval cholecystectomy in acute cholecystitis: an experience at Ghurki trust teaching Hospital, Lahore. *Pakistan J Medical Health Sci* 2014;8:778–81.
- 53 Zhang J, Li N-ping, Huang B-cang, *et al.* The value of performing early Non-enhanced CT in developing strategies for treating acute gallstone pancreatitis. *J Gastrointest Surg* 2016;20:604–10.
- 54 Boerma D, Rauws EAJ, Keulemans YCA, *et al.* Wait-and-see policy or laparoscopic cholecystectomy after endoscopic sphincterotomy for bile-duct stones: a randomised trial. *Lancet* 2002;360:761–5.
- 55 Heo J, Jung MK, Cho CM. Should prophylactic cholecystectomy be performed in patients with concomitant gallstones after endoscopic sphincterotomy for bile duct stones? *Surg Endosc* 2015;29:1574–9.
- 56 Lau JYW, Leow C-K, Fung TMK, *et al.* Cholecystectomy or gallbladder in situ after endoscopic sphincterotomy and bile duct stone removal in Chinese patients. *Gastroenterology* 2006;130:96–103.
- 57 Schmidt M, Söndena K, Vetrhus M, *et al.* Long-Term follow-up of a randomized controlled trial of observation versus surgery for acute cholecystitis: non-operative management is an option in some patients. *Scand J Gastroenterol* 2011;46:1257–62.
- 58 Zargar SA, Mushtaq M, Beg MA, *et al.* Wait-and-see policy versus cholecystectomy after endoscopic sphincterotomy for bile-duct stones in high-risk patients with co-existing gallbladder stones: a prospective randomised trial. *Arab J Gastroenterol* 2014;15:24–6.
- 59 Hammarström LE, Holmin T, Stridbeck H, *et al.* Long-Term follow-up of a prospective randomized study of endoscopic versus surgical treatment of bile duct calculi in patients with gallbladder in situ. *Br J Surg* 1995;82:1516–21.
- 60 Suc B, Escat J, Cherqui D, *et al.* Surgery vs endoscopy as primary treatment in symptomatic patients with suspected common bile duct stones: a multicenter randomized trial. French associations for surgical research. *Arch Surg* 1998;133:702–8.
- 61 Targarona EM, Ayuso RM, Bordas JM, *et al.* Randomised trial of endoscopic sphincterotomy with gallbladder left in situ versus open surgery for common bile duct calculi in high-risk patients. *Lancet* 1996;347:926–9.
- 62 Al-Kubati WR. Bile duct injuries following laparoscopic cholecystectomy: a clinical study. *Saudi J Gastroenterol* 2010;16:100–4.
- 63 Söderlund C, Frozanpor F, Linder S. Bile duct injuries at laparoscopic cholecystectomy: a single-institution prospective study. acute cholecystitis indicates an increased risk. *World J Surg* 2005;29:987–93.
- 64 Bender R. Using and interpreting adjusted NNT measures in biomedical research. *Open Dent J* 2010;4:72–6.
- 65 Chong CAKY, Tomlinson G, Chodirker L, *et al.* An unadjusted NNT was a moderately good predictor of health benefit. *J Clin Epidemiol* 2006;59:224–33.

## Online Supplementary Material

- **Supplementary Figures – Page 2-14**
- **Supplementary Tables - Page 15-24**
- **Prisma checklist - Page 25-26**

## Supplementary Figures


S. No	Study	D1	D2	D3	D4	D5	Overall
1	Aboulian_2010	+	+	+	+	+	+
2	Ammar_2014	+	+	+	+	+	+
3	El_Nakeeb_2016	+	+	+	+	+	+
4	Ozkardes_2014	+	+	+	+	+	+
5	Saber_2014	+	+	+	+	+	+
6	Abbas_2013	-	-	-	+	+	-
7	Gul_2013	+	+	!	+	+	!
8	Khalid_2017	-	+	+	!	+	-
9	Kolla_2004	+	+	+	+	+	+
10	Lai_1998	+	-	-	+	+	-
11	Gutt_2013	+	+	+	+	+	+
12	Muhammedoglu_2020	+	+	+	+	+	+
13	Macafee_2009	+	+	+	+	+	+
14	Mau Lo_1998	+	+	+	+	+	+
15	Rajcok_2016	-	-	-	-	!	-
16	Roulin_2016	+	+	+	+	+	+
17	Agrawal_2015	-	+	+	+	+	-
18	da Costa_2015	+	+	+	+	+	+
19	Boerma_2002	+	!	+	+	+	!
20	Stone_1981	-	-	-	+	!	-
21	Lahtinen_1978	+	-	-	+	-	-
22	Lau_2006	+	+	+	+	+	+
23	Norby_1983	-	!	+	+	!	-
24	Salman_2009	!	+	+	+	+	!
25	Reinders_2010	+	+	+	+	+	+
26	Heo_2014	+	-	+	+	+	-
27	Mcarthur_1975	+	-	-	+	!	-
28	Noel_2018	+	-	-	+	+	-
29	Jarvinen_1980	+	+	+	+	+	+
30	Zahur_2014	-	-	+	!	!	-
31	Jee_2016	+	!	+	+	!	!
32	Zargar_2014	+	+	+	+	!	!
33	Verma_2013	+	+	+	+	+	+
34	Yadav_2009	+	+	+	+	+	+
35	Hammarstrom_1995	+	+	+	+	+	+
36	Suc_1998	+	+	+	+	+	+
37	Targarona_1996	+	+	+	+	+	+
38	Schmidt_b_2011	+	+	+	+	+	+
39	Schmidt_a_2011	+	+	+	+	+	+
40	Zhang_2016	!	+	+	+	!	!

 Low risk  
 Some concerns  
 High risk

**Supplementary Figure 1: Assessment of Risk of Bias**


Bias due to D1-Randomization process; D2-Deviation from intended intervention; D3-Missing outcome data; D4- Measurement of outcome; D5-Selection of reported result.

Supplementary Figures




Supplementary Figure 2: Subgroup analysis of Pain/Biliary Colic in early cholecystectomy (EC) versus observation management (OM) by Baseline gallstone complication.

Supplementary Figures




**Supplementary Figure 3:** Subgroup analysis of Pain/Biliary Colic in Early Cholecystectomy (EC) versus Delayed Cholecystectomy (DC) by Baseline gallstone complication.

## Supplementary Figures




**Supplementary Figure 4:** Funnel and contour-enhanced funnel plots of early versus delayed cholecystectomy for Pain/Biliary Colic

Supplementary Figures




**Supplementary Figure 5:** Subgroup analysis of Total biliary complications in early cholecystectomy (EC) versus observation management (OM) by Baseline gallstone complication.

Supplementary Figures




**Supplementary Figure 6:** Subgroup analysis of Total biliary complications in Early Cholecystectomy (EC) versus Delayed Cholecystectomy (DC) by Baseline gallstone complication.

## Supplementary Figures




**Supplementary Figure 7:** Funnel and contour-enhanced funnel plots of early cholecystectomy versus entirely/relatively conservative management for Total Biliary Complications

Supplementary Figures




**Supplementary Figure 8:** Subgroup analysis of Mortality in early cholecystectomy (EC) versus observation management (OM) by Baseline gallstone complication.

Supplementary Figures




**Supplementary Figure 9:** Subgroup analysis of Mortality in Early Cholecystectomy (EC) versus Delayed Cholecystectomy (DC) by Baseline gallstone complication.

## Supplementary Figures




**Supplementary Figure 10:** Funnel and contour-enhanced funnel plots of early cholecystectomy versus conservative management for Mortality

Supplementary Figures



**Supplementary Figure 11:** Subgroup analysis of Conversion to laparotomy in Early Cholecystectomy (EC) versus Delayed Cholecystectomy (DC) by Baseline gallstone complication.

## Supplementary Figures



**Supplementary Figure 12:** Funnel and contour-enhanced funnel plots of early versus delayed cholecystectomy for Conversion to Laparotomy

## Supplementary Tables

Supplementary Table 1 Characteristics of included studies

Study	Country	Study Design	Baseline gallstone complication	Type of surgery	Groups (Sample size)	Age (Mean)	Gender (%)	Duration of symptoms (hours)	Timing of surgery
Muhammedoğlu et al 2020	Turkey	RCT-SC	CBD stones	LC	EC (n=82) DC (n=37)	61.5 53.5	- -	- -	Not Specified
									6-8 weeks
Noel et al 2018	Sweden	RCT-SC	Gallstone Pancreatitis	LC	EC (n=32) DC (n=34)	48 43.5	62.5% 55.9%	- -	within 48 hours
									6 weeks
Khalid et al 2017	Pakistan	RCT-SC	Cholecystitis	LC	EC (n=90) DC (n=90)	- -	- -	- -	within 72 hours
									6-8 weeks
El Nakeeb et al 2016	Egypt	RCT-SC	CBD stones	LC	EC (n=55) DC (n=55)	43 47	70.9% 65.5%	- -	within 72 hours
									after 1 month
Rajcok et al 2016	Slovakia	RCT-SC	Cholecystitis	LC	EC (n=31) DC (n=31)	56.3 59.8	48.30% 45.10%	- -	within 72 hours
									6-8 weeks
Roulin et al 2016	Switzerland	RCT-SC	Cholecystitis	LC	EC (n=42) DC (n=44)	55.8 57.9	43% 43%	96 96	within 72 hours
									after 6 weeks
Zhang et al 2016	China	RCT-SC	Gallstone Pancreatitis	LC	EC (n=49) DC (n=53)	62.1 63.5	57.1% 62.26%	- -	within 7 days
									>7 days
Jee et al 2016	Malaysia	RCT-SC	Gallstone Pancreatitis	LC	EC (n=38) DC (n=34)	42.5 42.5	52.63% 61.76%	- -	within 7 days
									6-8 weeks
da Costa et al 2015	Netherlands	RCT-MC	Gallstone Pancreatitis	LC	EC (n=128) DC (n=136)	53 54	59% 62%	- -	within 72 hours
									25-30 days
Agrawal et al 2015	India	RCT-SC	Cholecystitis	LC	EC (n=25) DC (n=25)	47.28 50.96	68% 68%	35.44 36.8	within 24 hours
									6-8 weeks
Ammar et al 2014	Egypt	RCT-SC	CBD stones	LC	EC (n=31) DC (n=29)	46.2 47.3	67.70% 724%	- -	within 24 hours
									>24 hours
3Heo et al 2014	Korea	RCT-SC	CBD stones	LC	CH (n=43) CM (n=45)	64.02 63.96	41.9% 44.4%	- -	-
									-
Zahur et al 2014	Pakistan	RCT-SC	Cholecystitis	LC	EC (n=47) DC (n=41)	- -	- -	- -	within 48 hours
									6-8 weeks

## Supplementary Tables

Study	Country	Study Design	Baseline gallstone complication	Type of surgery	Groups (Sample size)	Age (Mean)	Gender (%)	Duration of symptoms (hours)	Timing of surgery
Zargar et al 2014	India	RCT-SC	CBD stones	-	CH (n=80)	78.2	-	-	-
					CM (n=82)	77.3	-	-	-
Gul et al 2013	India	RCT-SC	Cholecystitis	LC	EC (n=30)	39.83	-	-	within 72 hours
					DC (n=30)	38.27	-	-	6-12 weeks
Verma et al 2013	India	RCT-SC	Cholecystitis	LC	EC (n=30)	31.73	86.6%	-	within 72 hours
					DC (n=30)	32.8	93.3%	-	6-8 weeks
Schmidt et al a et al 2011	Norway	RCT-MC	Cholecystitis	LC	CH (n=31)	55.5	60.6%	-	-
					CM (n=33)	61	54.8%	-	-
Schmidt et al b et al 2011	Norway	RCT-MC	Uncomplicated gallstones	LC	CH (n=68)	52	80.9%	-	-
					CM (n=69)	54	82.6%	-	-
Aboulian et al 2010	USA	RCT-SC	Gallstone Pancreatitis	LC	EC (n=25)	33	8%	48	within 48 hours
					DC (n=25)	41	12%	48	Not specified
Reinders et al 2010	Netherlands	RCT-MC	CBD stones	LC	EC (n=47)	55	76.5%	-	within 72 hours
					DC (n=47)	47	61.7%	-	6-8 weeks
Salman et al 2009	Turkey	RCT-SC	CBD stones	LC	EC (n=39)	43.5	66.60%	-	within 48 hours
					DC (n=40)	44.6	70%	-	within 72 hours to 7 days
Yadav et al 2009	Nepal	RCT-SC	Cholecystitis	LC	EC (n=25)	42.68	-	-	within 48 hours
					DC (n=25)	40.26	-	-	6-8 weeks
Kolla et al 2004	India	RCT-SC	Cholecystitis	LC	EC (n=20)	41.5	85%	35.1	within 24 hours
					DC (n=20)	38.6	75%	36.1	6-12 weeks
Lai et al 1998	Hong Kong	RCT-SC	Cholecystitis	LC	EC (n=53)	55.8	56.60%	-	within 24 hours
					DC (n=51)	56.1	70.50%	-	6-8 weeks
Mau Lo et al 1998	Hong Kong, China	RCT-SC	Cholecystitis	LC	EC (n=45)	59	42.20%	48	within 72 hours
					DC (n=41)	61	48.70%	48	8-12 weeks
Norby et al 1983	Sweden	RCT-MC	Cholecystitis	OC	EC (n=101)	58	65.30%	-	within 7 days
					DC (n=91)	58	61.50%	-	Not specified
Jarvinen et al 1980	Finland	RCT-SC	Cholecystitis	OC	EC (n=80)	57.8	50%	52.8	within 7 days
					DC (n=75)	56.7	52%	55.2	8-16 weeks

## Supplementary Tables

Study	Country	Study Design	Baseline gallstone complication	Type of surgery	Groups (Sample size)	Age (Mean)	Gender (%)	Duration of symptoms (hours)	Timing of surgery
Mcarthur et al 1975	United Kingdom	RCT-SC	Cholecystitis	OC	EC (n=15)	48.9	82.3%	38.1	Not Specified
					DC (n=17)	49.8	93.3%	47.9	8-12 weeks
Ozkardes et al 2014	Turkey	RCT-SC	Cholecystitis	LC	EC (n=30)	58.03	66.70%	-	within 24 hours
					DC (n=30)	59.43	56.70%	-	6-8 weeks
Saber et al 2014	Egypt	RCT-MC	Cholecystitis	LC	EC (n=60)		75%	-	within 72 hours
					DC (n=60)		70%	-	6-8 weeks
Abbas et al 2013	Pakistan	RCT-SC	Gallstone Pancreatitis	OC	EC (n=31)	40.22	83.80%	-	Not Specified
					DC (n=31)	53.51	83.80%	-	6-8 weeks
Gutt et al 2013	Germany	RCT-MC	Cholecystitis	LC	EC (n=304)	55.6	62.8%	-	within 24 hours
					DC (n=314)	56.8	54.8%	-	7-45 days
Macafee et al 2009	United Kingdom	RCT-SC	Cholecystitis	LC	EC (n=36)	52	72.20%	-	within 72 hours
					DC (n=36)	53	58.30%	-	after 3 months
Lau et al 2006	China	RCT-SC	CBD stones	LC	CH (n=89)	43	51.7%	-	-
					CM (n=89)	49	44.9%	-	-
Boerma et al 2002	Netherlands	RCT-MC	CBD stones	LC	CH (n=56)	60	59%	-	-
					CM (n=64)	63	51%	-	-
Suc et al 1998	France	RCT-MC	CBD stones	OC	CH (n=105)	66.7	68.50%	-	-
					EM (n=97)	66.8	68.04%	-	-
Targarona et al 1996	Spain	RCT-SC	CBD stones	OC	CH (n=48)	80	68.75%	-	-
					EM (n=50)	79	70%	-	-
Hammarstrom et al 1995	Sweden	RCT-SC	CBD stones	OC	CH (n=41)	73.5	-	-	-
					EM (n=39)	75	-	-	-
Stone et al 1981	Georgia	RCT-SC	Gallstone Pancreatitis	OC	EC (n=36)	-	-	-	within 72 hours
					DC (n=34)	-	-	-	3-6 months
Lahtinen et al 1978	Finland	RCT-SC	Cholecystitis	OC	EC (n=47)	63.8	60%	-	within 7 days
					DC (n=44)	62.8	60%	-	8-12 weeks

RCT-Randomized Control Trial; MC-Multicentre; SC-Single Centre; LC-Laparoscopic Cholecystectomy; OC- Open Cholecystectomy; EC- Early Cholecystectomy; DC- Delayed Cholecystectomy; CM-Conservative Management; EM- Endoscopic Management; Ch-Cholecystectomy; CBD- Common Bile Duc

## Supplementary Tables

**Supplementary Table 2: Subgroup analysis of surgical complications of early cholecystectomy (EC) versus delayed cholecystectomy (DC) based on timing of surgery**

Surgical Complications	Timing of surgery	RR (95% CI)	I <sup>2</sup> (%)	Q	References
Total Intra-operative complications	EC within 7 days (2)	1.21 (0.15 to 9.65)	18.99%	1.23	13 24
	EC within 72 hours (3)	0.95 (0.28 to 3.20)	61.33%	5.17	11 25 26
	DC <6 weeks (1)	1.02 (0.02 to 50.42)	-	-	25
	DC >6 weeks (3)	0.83 (0.24 to 2.84)	64.54%	5.64	11 24 26
	Overall (5)	1.00 (0.40 to 2.51)	38.64%	6.52	
Total Post-operative complications	EC within 7 days (1)	0.89 (0.19 to 4.14)	-	-	24
	EC within 72 hours (11)	0.94 (0.68 to 1.29)	0%	8.01	1 5 8 9 18-22 25 26
	DC <6 weeks (1)	0.26 (0.03 to 2.19)	-	-	25
	DC >6 weeks (11)	0.97 (0.70 to 1.32)	0%	6.58	1 5 8 9 18-22 25 26
	Overall (12)	0.94 (0.69 to 1.28)	0%	8.02	
Total Surgical complications	EC within 7 days (3)	0.83 (0.53 to 1.31)	0%	0.16	7 13 24
	EC within 72 hours (12)	1.35 (1.02 to 1.79)	0%	9.52	1 6 8 9 14 17 19-21 23 26 28
	DC <6 weeks (2)	0.98 (0.50 to 1.91)	0%	0.09	6 14
	DC >6 weeks (14)	1.23 (0.94 to 1.62)	3.51%	13.47	1 7-9 15 17 19-21 23 24 26-28
	Overall (17)	1.15 (0.91 to 1.45)	0%	14.63	
Mortality	EC within 7 days (3)	0.25 (0.04 to 1.62)	0%	0.78	12 13 24
	EC within 72 hours (6)	0.97 (0.27 to 3.51)	0%	0.9	6 8 9 14 21 23
	DC <6 weeks (2)	1.67 (0.21 to 13.55)	0%	0.27	6 14
	DC >6 weeks (7)	0.59 (0.21 to 1.69)	0%	3.40	8 9 12 21 23 24 30
	Overall (9)	0.63 (0.22 to 1.8)	0%	3.06	
Conversion to Laparotomy	EC within 7 days (2)	0.78 (0.23 to 2.63)	0%	0.27	10 24
	EC within 72 hours (18)	1.01 (0.75 to 1.37)	0%	12.97	1-5 8 9 11 14 16-18 20 22 25 26 28 29
	DC <6 weeks (5)	0.71 (0.36 to 1.43)	0%	3.46	2 3 10 14 25
	DC >6 weeks (15)	1.07 (0.78 to 1.48)	0%	8.87	1 4 5 8 9 11 16-18 20 22 24 26 28 29
	Overall (20)	1.00 (0.74 to 1.34)	0%	13.40	

## Supplementary Tables

**Supplementary Table 4: Risk ratios of biliary complications in early cholecystectomy versus conservative management (Observation and Endoscopic management)**

Complications (no. of studies)	RR (CI)	I <sup>2</sup>	Q	Reference
Pain/Biliary Colic (7)	0.39 (0.21 to 0.75)	13.20%	6.91	31 32 33-37
Biliary Pancreatitis (5)	0.99 (0.25 to 3.90)	0%	0.98	31 38 35-37 38
Acute cholecystitis (9)	0.09 (0.03 to 0.23)	0%	1.13	31 32 38 33-37 39
CBD stones (2)	0.35 (0.06 to 2.15)	0%	0.00	35 36
Cholangitis (6)	0.52 (0.28 to 0.97)	0%	3.76	32-34 37 38
<b>Total Biliary complications (6)</b>	0.33 (0.21 to 0.51)	22.7%	6.47	32 34-37 39
Mortality (6)	0.80 (0.49 to 1.30)	0%	2.86	32-34 36-38

## Supplementary Tables

Supplementary Table 5. Search terms and no. of hits in PubMed

PICOS	Pubmed Search terms	Hits (on date 16th July 2020)
<b>P</b>	"gall bladder" OR gallbladder OR cholecystitis OR cholelithiasis OR gallstone OR "gall stone" OR "gall stones" OR cholelithiasis OR "bile duct stone" OR "common bile duct" OR CBD OR "biliary disease" OR "biliary tract disease" OR cholec* OR "gallbladder inflammation"	<b>151,737</b>
<b>I</b>	cholecystectomy OR "gallbladder removal" OR "gallbladder excision" OR ("surgical removal" AND ("gall bladder" OR gallbladder)) OR ("surgical excision" AND ("gall bladder" OR gallbladder)) OR "restrictive strategy" OR cholecystostomy OR "biliary tract surgery" OR "bile duct operation" OR "bile duct surgery" OR "bile tract surgery" OR "biliary surgery" OR "biliary tract operation" OR "biliary tract reoperation" OR "biliary tract surgery" OR "biliary tract surgical procedures" OR "gall bladder surgery" OR "gallbladder operation" OR "gallbladder surgery" OR sphincterotomy	<b>55,069</b>
<b>C</b>	"conservative treatment" OR "conservative management" OR "conservative therapy" OR "nonoperative treatment" OR "nonsurgical treatment" OR 'organ sparing treatment' OR 'organ sparing treatments' OR supportive OR non-invasive OR non-surgical OR non-operative OR "wait and watch" OR "wait and see" OR watchful-waiting OR "usual care"	<b>10,190,039</b>
<b>S</b>	"randomized controlled trial" [pt] OR "controlled clinical trial" [pt] OR randomized [tiab] OR placebo [tiab] OR "drug therapy" [sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab]	<b>4,809,100</b>
<b>PICS</b>	<b>PICS</b>	<a href="#">1742</a>
<b>Additional search with new search terms</b>	(Lithotripsy OR dissolution OR "ursodeoxycholic acid" OR "endoscopic retrograde cholangiopancreatography" OR "Percutaneous cholecystolithotomy" OR "methyl tert-butyl ether" OR ursodiol)) NOT PICS	130
<b>Updated search</b>	Updated search as on 12 <sup>th</sup> January 2021	74
	<b>Total</b>	<b>1945</b>

## Supplementary Tables

Supplementary Table 6. Search terms and no. of hits in Embase

PICOS	EMBASE Search terms	Hits (on date 16th July 2020)
<b>P</b>	'gall bladder'/exp OR 'gall bladder' OR 'gallbladder'/exp OR gallbladder OR 'cholecystitis'/exp OR cholecystitis OR 'cholelithiasis'/exp OR cholelithiasis OR 'gallstone'/exp OR gallstone OR 'gall'/exp OR gall OR 'cholecystolithiasis'/exp OR cholecystolithiasis OR 'calculi'/exp OR calculi OR 'choledocholithiasis'/exp OR choledocholithiasis OR 'bile duct stone'/exp OR 'bile duct stone' OR 'cbd stone' OR 'biliary disease'/exp OR 'biliary disease' OR 'biliary tract disease'/exp OR 'biliary tract disease' OR "gallbladder inflammation"	<b>356,517</b>
<b>I</b>	cholecystectomy OR 'gallbladder removal' OR 'gallbladder excision' OR ('surgical removal' AND ('gall bladder' OR gallbladder)) OR ('surgical excision' AND ('gall bladder' OR gallbladder)) OR 'restrictive strategy' OR cholecystostomy OR 'biliary tract surgery'/exp OR 'bile duct operation' OR 'bile duct surgery' OR 'bile tract surgery' OR 'biliary surgery' OR 'biliary tract operation' OR 'biliary tract reoperation' OR 'biliary tract surgery' OR 'biliary tract surgical procedures' OR 'gall bladder surgery' OR 'gallbladder operation' OR 'gallbladder surgery' OR 'sphincterotomy, transhepatic' OR 'surgery, biliary tract'	<b>89,610</b>
<b>C</b>	'conservative management' OR 'conservative therapy' OR 'conservative treatment' OR 'nonoperative treatment' OR 'nonsurgical treatment' OR 'organ sparing treatment' OR 'organ sparing treatments' OR 'treatment, conservative' OR analges* OR 'non-steroid anti-inflammatory' OR 'non-steroidal anti-inflammatory' OR nsaid OR 'anti inflammatory' OR antinflammatory OR antibiotic* OR supportive OR 'non invasive' OR 'non surgical' OR 'non operative' OR 'wait and watch' OR 'wait and see' OR 'watchful waiting' OR 'usual care'	<b>1,783,181</b>
<b>S</b>	trial OR trail OR blind OR rct OR randomization OR randomisation OR randomized OR randomised OR placebo OR 'randomized control trial' OR 'randomized controlled trial' OR 'randomized controlled trail' OR 'randomized control trail' OR 'controlled clinical trial' OR randomly OR groups OR 'randomised controlled study' OR 'randomized controlled study'	<b>5,139,403</b>
<b>PICS</b>		<b>1646</b>

## Supplementary Tables

Supplementary Table 7. Search terms and no. of hits in Scopus

PIC OS	SCOPUS Search terms	Hits (on 16th July 2020)
<b>P</b>	ALL("gallbladder" OR gallbladder OR cholecystitis OR cholecystitis OR cholelithiasis OR cholelithiasis OR "gall stone" OR gallstone OR cholecystolithiasis OR calculi OR choledocholithiasis OR choledocholithiasis OR "bile duct stone" OR "cbd stone" OR "biliary disease" OR "biliary tract disease" OR "Gallbladder inflammation" )	<b>630,221</b>
<b>I</b>	ALL ( cholecystectomy OR "gallbladder removal" OR "gallbladder excision" OR ( "surgical removal" AND ( "gall bladder" OR gallbladder ) ) OR ( "surgical excision" AND ( "gall bladder" OR gallbladder ) ) OR "restrictive strategy" OR cholecystostomy OR "biliary tract operation" OR "biliary tract reoperation" OR "biliary tract surgical procedures" OR "gallbladder operation" OR sphincterotomy OR ( surger* AND (gall OR biliar*) )	<b>283,560</b>
<b>C</b>	ALL ( conservative OR observatio* OR analgesi* OR (nonsteroid AND anti-inflammatory) OR "non-steroidal anti-inflammatory" OR nsaid OR anti-inflammatory OR antinflammatory OR anti-infective OR anti-bacterial OR supportive OR non-invasive OR noninvasive OR non-surgical OR nonsurgical OR non-operative OR nonoperative OR "wait and watch" OR "wait and see" OR watchful-waiting OR "usual care" )	<b>9,204,582</b>
<b>S</b>	ALL ( trial OR trail OR blind OR rct OR randomization OR randomisation OR randomized OR randomised OR placebo OR 'randomized control trial' OR 'randomized controlled trial' OR 'randomized controlled trail' OR 'randomized control trail' OR 'controlled clinical trial' OR randomly OR groups OR 'randomised controlled study' OR 'randomized controlled study' )	<b>1,184,853</b>
<b>PIC S</b>	Limited only to journal	<b>2.903</b>

## Supplementary Tables

## References :

1. Agrawal R, Sood KC, Agarwal B. Evaluation of Early versus Delayed Laparoscopic Cholecystectomy in Acute Cholecystitis. *Surg Res Pract* 2015;2015:349801.
2. Ammar SA, Bar MA, El Shafy M. Laparoscopic cholecystectomy after endoscopic retrograde cholangiopancreatography: The optimal timing for operation. *World Journal of Laparoscopic Surgery* 2014;7(2):69-73.
3. El Nakeeb A, Ezzet H, Askar W, et al. Early Versus Late Cholecystectomy after Clearance of Common Bile Duct Stones by Endoscopic Retrograde Cholangiopancreatography: A Prospective Randomized Study. *Surgical Laparoscopy, Endoscopy and Percutaneous Techniques* 2016;26(3):202-207.
4. Zahur S, Rabbani S, Andrabi SIH, et al. Early vs interval cholecystectomy in acute cholecystitis: An experience at Ghurki Trust Teaching Hospital, Lahore. *Pakistan Journal of Medical and Health Sciences* 2014;8(3):778-781.
5. Gul R, Dar RA, Sheikh RA, et al. Comparison of early and delayed laparoscopic cholecystectomy for acute cholecystitis: Experience from a single center. *North American Journal of Medical Sciences* 2013;5(7):414-418.
6. Gutt CN, Encke J, Königer J, et al. Acute cholecystitis: early versus delayed cholecystectomy, a multicenter randomized trial (ACDC study, NCT00447304). *Ann Surg* 2013;258(3):385-393.
7. Järvinen HJ, Hästbacka J. Early cholecystectomy for acute cholecystitis: a prospective randomized study. *Ann Surg* 1980;191(4):501-505.
8. Khalid S, Iqbal Z, Bhatti AA. Early Versus Delayed Laparoscopic Cholecystectomy For Acute Cholecystitis. *Journal of Ayub Medical College, Abbottabad : JAMC* 2017;29(4):570-573.
9. Kolla SB, Aggarwal S, Kumar A, et al. Early versus delayed laparoscopic cholecystectomy for acute cholecystitis: a prospective randomized trial. *Surg Endosc*;18(9):1323-1327.
10. Zhang J, Li NP, Huang BC, et al. The Value of Performing Early Non-enhanced CT in Developing Strategies for Treating Acute Gallstone Pancreatitis. *J Gastrointest Surg*;20(3):604-610.
11. Lo CM, Liu CL, Fan ST, et al. Prospective randomized study of early versus delayed laparoscopic cholecystectomy for acute cholecystitis. *Annals of Surgery* 1998;227(4):461-467.
12. Lahtinen J, Alhava EM, Aukee S. Acute cholecystitis treated by early and delayed surgery. A controlled clinical trial. *Scand J Gastroenterol* 1978;13(6):673-678.
13. Norby S, Herlin P, Holmin T. Early or delayed cholecystectomy in acute cholecystitis? A clinical trial. *British Journal of Surgery* 1983;70(3):163-165.
14. da Costa DW, Bouwense SA, Schepers NJ, et al. Same-admission versus interval cholecystectomy for mild gallstone pancreatitis (PONCHO): a multicentre randomised controlled trial. *Lancet* 2015;386(10000):1261-1268.
15. McArthur P, Cuschieri A, Sells RA, et al. Controlled clinical trial comparing early with interval cholecystectomy for acute cholecystitis. *Br J Surg* 1975;62(10):850-852.
16. Rajcok M, Bak V, Danihel L, et al. Early versus delayed laparoscopic cholecystectomy in treatment of acute cholecystitis. *Bratislavske lekarske listy* 2016;117(6):328-331.
17. Saber A, Hokkam EN. Operative outcome and patient satisfaction in early and delayed laparoscopic cholecystectomy for acute cholecystitis. *Minim Invasive Surg* 2014;2014:162643.
18. Lai PB, Kwong KH, Leung KL, et al. Randomized trial of early versus delayed laparoscopic cholecystectomy for acute cholecystitis. *Br J Surg*;85(6):764-767.
19. Macafee DA, Humes DJ, Bouliotis G, et al. Prospective randomized trial using cost-utility analysis of early versus delayed laparoscopic cholecystectomy for acute gallbladder disease. *Br J Surg* 2009;96(9):1031-1040.
20. Noel R, Arnelo U, Lundell L, et al. Index versus delayed cholecystectomy in mild gallstone pancreatitis: results of a randomized controlled trial. *HPB (Oxford)* 2018;20(10):932-938.

## Supplementary Tables

21. Reinders JS, Goud A, Timmer R, et al. Early laparoscopic cholecystectomy improves outcomes after endoscopic sphincterotomy for choledochocystolithiasis. *Gastroenterology* 2010;138(7):2315-2320.
22. Roulin D, Saadi A, Di Mare L, et al. Early versus delayed cholecystectomy for acute cholecystitis, are the 72 hours still the rule? A randomized trial. *Annals of Surgery* 2016;264(5):717-722.
23. Stone HH, Fabian TC, Dunlop WE. Gallstone pancreatitis: biliary tract pathology in relation to time of operation. *Ann Surg*;194(3):305-312.
24. Jee SL, Jarmin R, Lim KF, et al. Outcomes of early versus delayed cholecystectomy in patients with mild to moderate acute biliary pancreatitis: A randomized prospective study. *Asian J Surg* 2018;41(1):47-54.
25. Salman B, Yilmaz U, Kerem M, et al. The timing of laparoscopic cholecystectomy after endoscopic retrograde cholangiopancreatography in cholelithiasis coexisting with choledocholithiasis. *J Hepatobiliary Pancreat Surg* 2009;16(6):832-836.
26. Yadav RP, Adhikary S, Agrawal CS, et al. A comparative study of early vs. delayed laparoscopic cholecystectomy in acute cholecystitis. *Kathmandu University Medical Journal* 2009;7(25):16-20.
27. Abbas A, Umair M, Isnain HG, et al. Early cholecystectomy vs delayed cholecystectomy for gall stone pancreatitis. *Pakistan Journal of Medical and Health Sciences* 2013;7(1):87-89.
28. Ozkardeş AB, Tokaç M, Dumlu EG, et al. Early versus delayed laparoscopic cholecystectomy for acute cholecystitis: a prospective, randomized study. *Int Surg* 2014;99(1):56-61.
29. Verma S, Agarwal PN, Bali RS, et al. Early versus Delayed Laparoscopic Cholecystectomy for Acute Cholecystitis: A Prospective Randomized Trial.
30. Aboulian A, Chan T, Yaghoubian A, et al. Early cholecystectomy safely decreases hospital stay in patients with mild gallstone pancreatitis: A randomized prospective study. *Annals of Surgery* 2010;251(4):615-619.
31. Hammarström LE, Holmin T, Stridbeck H, et al. Long-term follow-up of a prospective randomized study of endoscopic versus surgical treatment of bile duct calculi in patients with gallbladder in situ. *Br J Surg* 1995;82(11):1516-1521.
32. Targarona EM, Ayuso RM, Bordas JM, et al. Randomised trial of endoscopic sphincterotomy with gallbladder left in situ versus open surgery for common bile duct calculi in high-risk patients. *Lancet* 1996;347(9006):926-929.
33. Boerma D, Rauws EA, Keulemans YC, et al. Wait-and-see policy or laparoscopic cholecystectomy after endoscopic sphincterotomy for bile-duct stones: a randomised trial. *Lancet*;360(9335):761-765.
34. Lau JYW, Leow C-K, Fung TMK, et al. Cholecystectomy or gallbladder in situ after endoscopic sphincterotomy and bile duct stone removal in Chinese patients. *Gastroenterology* 2006;130(1):96-103.
35. Schmidt M, Søndena K, Vetrhus M, et al. A Randomized Controlled Study of Uncomplicated Gallstone Disease with a 14-Year Follow-Up Showed that Operation Was the Preferred Treatment. *Digestive Surgery* 2011;28(4):270-276.
36. Schmidt M, Søndena K, Vetrhus M, et al. Long-term follow-up of a randomized controlled trial of observation versus surgery for acute cholecystitis: Non-operative management is an option in some patients. *Scandinavian Journal of Gastroenterology* 2011;46(10):1257-1262.
37. Zargar SA, Mushtaq M, Beg MA, et al. Wait-and-see policy versus cholecystectomy after endoscopic sphincterotomy for bile-duct stones in high-risk patients with co-existing gallbladder stones: a prospective randomised trial. *Arab Journal of Gastroenterology: The Official Publication of the Pan-Arab Association of Gastroenterology* 2014;15(1):24-26.
38. Suc B, Escat J, Cherqui D, et al. Surgery vs endoscopy as primary treatment in symptomatic patients with suspected common bile duct stones: a multicenter randomized trial. French Associations for Surgical Research. *Arch Surg* 1998;133(7):702-708.

**Supplementary Tables**

39. Heo J, Jung MK, Cho CM. Should prophylactic cholecystectomy be performed in patients with concomitant gallstones after endoscopic sphincterotomy for bile duct stones? *Surgical Endoscopy* 2015;29(6):1574-1579.

## PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
<b>TITLE</b>			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	Yes, 1
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	Yes, 2
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	Yes, 4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	Yes, 4
<b>METHODS</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	Yes, 4
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	Yes, 5
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	Yes, 5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	Yes, 4 & appendix A
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	Yes, 5
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	Yes, 6
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	Yes, 6
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	Yes, 6
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	Yes, 7
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I <sup>2</sup> ) for each meta-analysis.	Yes, 7

## PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	Yes 8
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	Yes, 7
<b>RESULTS</b>			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	Yes, 8 & 9
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	Yes, 9
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	Yes, 9& 10
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	Yes, 10-15 Figure 2 & 3, Table 1&2, Supp figures 1-20
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	Yes, 10-15
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	Yes, 10-15 Supp Figures 4,14,17,20
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	Supp Table 1&2, Supp Figures 2-11, 13, 15,16,18,19
<b>DISCUSSION</b>			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	Yes, 16 & 17
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	Yes, 18
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	Yes, 18
<b>FUNDING</b>			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	Yes, 1

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097